Scientists at the Scripps Institute designed a new class of PPAR-gamma activating diabetes drugs that reprogram insulin-resistant cells into a healthier state— with far fewer side effects than older PPAR-gamma medications like Avandia (rosiglitazone) and Actos (pioglitazone)
How they work:
- Target PPAR-gamma, a master switch that controls fat cell and insulin metabolism
- Fine-tune its activity instead of blasting it wide open
- Tested on both mouse and human fat cells with promising results
- Published in Nature Communications
The older thiazolidinedione class of drugs (“glitazones”) can raise the risk for fluid retention, weight gain, bone loss, and heart failure.
Note that the PPAR-gamma pathway can be activated NATURALLY with linoleic acid, the primary omega 6 fat found in nuts and seeds:
↪ Omega-6 linoleic acid improves insulin sensitivity by activating PPAR-gamma
↪ Why omega-6 lowers diabetes risk: 43% lower risk in top vs bottom blood level quintile
facebook.com/share/v/1FVcgE9tVo
↪ Linoleic acid activates PPAR-gamma like pioglitazone, which may reverse plaque
PPAR-gamma activation appears to be the primary mechanism by which omega 6 fats in nuts and seeds improve glycemic control and insulin sensitivity, as demonstrated (in aggregate) in over 100 randomized trials in humans:
↪ 100+ trials: polyunsaturated fat improves glucose and insulin markers, saturated doesn't
↪ Meta-analysis of 102 feeding trials: PUFA gives the best glucose-insulin benefits
Nuts are life extension drugs:
↪ Nut eating >3 times a week tied to 39% lower all-cause mortality in PREDIMED
————-
Quoted from the article:
The [newly developed] compounds target a master regulator of fat cell and insulin metabolism called PPAR gamma. The protein plays a role in diabetes, inflammation, cancers, obesity, heart disease and osteoporosis, making it a sought-after but complex medicinal target.
Short for peroxisome proliferator-activated receptor gamma, the PPAR gamma protein is a type of nuclear receptor, meaning it binds to the cell's DNA, and can switch clusters of genes on and off.
Type 2 diabetes patients need better options, Griffin said. Uncontrolled, the condition can lead to heart disease, nerve and blood vessel damage, cognitive decline, vision problems and more. The front-line drug for type 2 diabetes, metformin, doesn't adequately improve insulin sensitivity, especially for high-risk patients with chronic kidney disease, he said. Newer diabetes drugs also carry risks for kidney disease patients, he said.
"PPAR gamma has been a notoriously difficult target, but it remains an essential one for helping patients who still lack safe, effective options," Griffin said. "What this study shows is that with the right tools and careful design, we can finally begin to overcome those barriers."
Developing medications that target PPAR gamma has been challenging, because of the multifaceted role it plays in biology. Several diabetes drugs known as glitazones, including Actos and Avandia, robustly improve insulin sensitivity by targeting PPAR gamma. However, they are also associated with serious side effects affecting the heart, bones, and, in some cases, cancer risk.
The U.S. Food and Drug Administration mandates a boxed warning for all glitazones, highlighting their potential to cause or exacerbate congestive heart failure.
The Griffin laboratory has spent more than 15 years developing alternative compounds that fine-tune PPAR gamma activity. The new approach should allow researchers to more accurately predict therapeutic outcomes based on compound design before drugs move into later stages of testing, the scientists said.
#linoleicacidHD #ppargammaHD #omega6HD #nutsHD #seedsHD #seedoilsHD #pioglitazoneHD #diabetesHD #insulinresistanceHD #thiazolidinedionesHD #rosiglitazoneHD
